Welcome to our dedicated page for IO Biotech news (Ticker: $IOBT), a resource for investors and traders seeking the latest updates and insights on IO Biotech stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IO Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IO Biotech's position in the market.
Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) reports completion of enrollment in pivotal Phase 3 trial of IO102-IO103 cancer vaccine in combination with KEYTRUDA®. Encouraging preliminary data from Phase 2 basket trial presented at major medical conferences. Company ended Q3 with $165.5 million in cash, expects to support operations into Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
-
Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) appoints industry veteran Dr. Helen Collins, MD, to its board of directors, signaling potential advancements in cancer vaccine development. Dr. Collins brings extensive drug development and corporate strategy experience and will serve on the Research and Development Committee. IO Biotech aims to potentially bring its lead cancer vaccine candidate, IO102-IO103, to market for advanced melanoma patients as early as 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
-
Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) completes enrollment in pivotal Phase 3 trial for IO102-IO103 in combination with KEYTRUDA® in patients with advanced melanoma. Phase 1/2 data showed promising results, with 80% of patients achieving a response and 50% achieving a complete response. The trial is expected to reach the primary endpoint of progression-free survival in the second half of 2025, with an interim analysis in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) announces participation in Jefferies London Healthcare Conference and Piper Sandler 35th Healthcare Conference. CEO Mai-Britt Zocca and CFO Amy Sullivan to attend one-on-one meetings in London. Fireside chat with CEO Mai-Britt Zocca at Piper Sandler conference in New York. Webcast link provided for the event. Webcast replay available on company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
-
Rhea-AI Summary
IO Biotech announces three poster presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting. Non-clinical data show the impact of immune modulating vaccines targeting IDO1 and PD-L1 on immune escape mechanisms in the tumor microenvironment, leading to enhanced anti-tumor effect. Clinical trials of IO102-IO103 with a PD-1 inhibitor demonstrated enhanced anti-tumor activity in multiple tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
-
Rhea-AI Summary
IO Biotech announces encouraging preliminary data from Phase 2 trial of IO102-IO103 in combination with Merck's KEYTRUDA® at ESMO Congress. 56% of NSCLC patients achieved partial response, indicating favorable activity compared to historical controls. Longer-term data needed for durability of response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
Rhea-AI Summary
IO Biotech announces three poster presentations at SITC 2023, showcasing new data on cancer vaccines
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
-
Rhea-AI Summary
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.23%
Tags
-
Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
Rhea-AI Summary
IO Biotech achieves significant enrollment milestone in Phase 3 trial of IO102-IO103 cancer vaccine, expects full enrollment by end of 2023. Ended Q2 with $110.1 million in cash. Positive outlook for second half of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
IO Biotech, Inc.
Nasdaq:IOBT
IOBT Rankings
IOBT Stock Data
81.03M
25.98M
2.95%
81.14%
0.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
COPENHAGEN
About IOBT
io biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of t cells that are specific for immune inhibitory molecules. io biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting ido and pd-l1 in clinical development and several compounds finalizing preclinical phase. io biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.